Patients with high cardiovascular risk as candidates to bempedoic acid after treatment with statins, ezetimibe and PCSK9 inhibitors. An estimation and cost-effectiveness analysis.

以兹提米比 医学 PCSK9 低密度脂蛋白胆固醇 估计 内科学 胆固醇 药理学 低密度脂蛋白受体 脂蛋白 经济 管理
作者
José Seijas‐Amigo,Alberto Cordero,Rosa Fernández Olmo,Gustavo A. Cortez Quiroga,Lorenzo Fácila,Ángel Salgado‐Barreira,Francisco Reyes-Santías,César Romero‐Menor,Juan Rondán,Moisés Rodríguez‐Mañero,M C Bello Mora,Alfonso Valle,Miriam Sandín,Román Freixa‐Pamias,Jordi Bañeras,Pedro Blanch García,Milagros Clemente Lorenzo,Sergio Sánchez‐Álvarez,Luis López‐Rodríguez,José Ramón González‐Juanatey
出处
期刊:Journal of Cardiovascular Pharmacology [Lippincott Williams & Wilkins]
卷期号:81 (1): 70-75 被引量:5
标识
DOI:10.1097/fjc.0000000000001365
摘要

Abstract: Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid is a novel oral drug in the therapeutic armamentarium which is able to reduce LDLc. The objectives of this study were (1) to select the potential patients for administering bempedoic acid such as those with a very high cardiovascular risk in which objectives of LDLc were not achieved despite conventional treatment with PCSK9 inhibitors (PCSK9i) and/or statins and ezetimibe and (2) to estimate the cost-effectiveness of bempedoic acid in different scenarios. The methods used were a multicenter and retrospective study of 652 patients initiating treatment with any PCSK9 inhibitor in 17 different hospitals. Before and on-treatment LDLc cholesterol levels, medical treatments, clinical indication, and baseline characteristics were recorded. The results obtained from 443 subjects in secondary prevention were analyzed. The mean (±) LDLc level at baseline was 142.5 ± 46.4 mg/dL and 61.5 ± 40.5 mg/dL in the follow-up, with a reduction of 55.9% ( P < 0.0001); 71.6% of the patients reached the target of LDL < 55 mg/dL or >50% reduction. Of those patients treated with medium-intensity and low-intensity statins plus PCSK9 inhibitors (with or without ezetimibe), only 5.7% of them were able to reduce LDL below 55 mg/dL and the main LDLc reduction in this group was the lowest (42.9% on average). Patients with TG values >135 mg/dL represented 41.6% of the sample, of which approximately 10% of them were using fibrates. Assuming only LDLc reduction and the UK price, the incremental cost-effectiveness ratio was 88,359€; 83,117€; 82,378€; and 79,015€ for different discount rates. In conclusion, one-third of the patients could achieve the target LDL proposed in the 2019 ESC/EAS guidelines. Approximately 10% of them could also benefit from treating hypertriglyceridemia as indicated in the 2021 ESC guidelines on cardiovascular disease prevention. Patients with medium-intensity and low-intensity statins plus PCSK9i and ezetimibe would be the most benefited. Bempedoic acid could be a not cost-efficacy therapy in all the scenarios, but we need to wait for the CLEAR OUTCOMES Trial results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
css1997完成签到 ,获得积分10
1秒前
无限飞丹完成签到,获得积分10
1秒前
小饭完成签到,获得积分10
1秒前
Cl1audia发布了新的文献求助10
2秒前
所所应助木可采纳,获得10
2秒前
Gyro完成签到,获得积分10
4秒前
隐形曼青应助lzx采纳,获得10
4秒前
5秒前
体贴紫完成签到,获得积分10
6秒前
6秒前
6秒前
7秒前
五六七完成签到,获得积分10
7秒前
7秒前
liz_发布了新的文献求助10
8秒前
新xin发布了新的文献求助10
9秒前
CodeCraft应助111111111采纳,获得10
10秒前
汉堡包应助秋天里的水采纳,获得10
11秒前
量子星尘发布了新的文献求助10
11秒前
Gyro发布了新的文献求助50
11秒前
慕青应助keyun采纳,获得10
11秒前
体贴紫发布了新的文献求助10
11秒前
12秒前
Dr.Who发布了新的文献求助10
13秒前
14秒前
深情安青应助科研通管家采纳,获得10
14秒前
彭于晏应助科研通管家采纳,获得10
14秒前
搜集达人应助科研通管家采纳,获得10
14秒前
顾矜应助科研通管家采纳,获得10
14秒前
华仔应助科研通管家采纳,获得10
14秒前
Owen应助科研通管家采纳,获得10
14秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
赘婿应助科研通管家采纳,获得10
15秒前
Ava应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
Owen应助科研通管家采纳,获得10
15秒前
桐桐应助科研通管家采纳,获得10
15秒前
dali完成签到 ,获得积分10
16秒前
accept发布了新的文献求助10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989444
求助须知:如何正确求助?哪些是违规求助? 3531531
关于积分的说明 11254250
捐赠科研通 3270191
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174